Glycorex Transplantation AB (GTAB B) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 125 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.23

Return on Equity

-20.29%

Price to Book

3.18

Revenue and Profits:

Net Sales:

10 Million

(Quarterly Results - Jun 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-5.0%

6 Months

-13.64%

1 Year

1.06%

2 Years

22.58%

3 Years

-54.55%

4 Years

-79.66%

5 Years

-84.68%

Glycorex Transplantation AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.31%

EBIT Growth (5y)

-200.96%

EBIT to Interest (avg)

-14.91

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.27

Sales to Capital Employed (avg)

0.70

Tax Ratio

0.67%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.87

EV to EBIT

-19.27

EV to EBITDA

74.01

EV to Capital Employed

4.74

EV to Sales

3.79

PEG Ratio

Dividend Yield

ROCE (Latest)

-24.61%

ROE (Latest)

-20.29%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 5.15% vs -7.62% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 35.29% vs 15.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.20",
          "val2": "9.70",
          "chgp": "5.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.40",
          "val2": "0.90",
          "chgp": "55.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.10",
          "val2": "-1.70",
          "chgp": "35.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-97.40%",
          "val2": "-147.50%",
          "chgp": "5.01%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.33% vs -16.90% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 64.14% vs -253.49% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.20",
          "val2": "30.00",
          "chgp": "17.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.50",
          "val2": "-25.90",
          "chgp": "82.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.30",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.90",
          "val2": "-30.40",
          "chgp": "64.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-296.90%",
          "val2": "-1,048.80%",
          "chgp": "75.19%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

10.20

9.70

5.15%

Operating Profit (PBDIT) excl Other Income

1.40

0.90

55.56%

Interest

0.10

0.20

-50.00%

Exceptional Items

0.00

Consolidate Net Profit

-1.10

-1.70

35.29%

Operating Profit Margin (Excl OI)

-97.40%

-147.50%

5.01%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 5.15% vs -7.62% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 35.29% vs 15.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

35.20

30.00

17.33%

Operating Profit (PBDIT) excl Other Income

-4.50

-25.90

82.63%

Interest

0.60

0.30

100.00%

Exceptional Items

0.00

Consolidate Net Profit

-10.90

-30.40

64.14%

Operating Profit Margin (Excl OI)

-296.90%

-1,048.80%

75.19%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 17.33% vs -16.90% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 64.14% vs -253.49% in Dec 2023

All Annual Results

Company CV

About Glycorex Transplantation AB

Glycorex Transplantation AB

Pharmaceuticals & Biotechnology

Glycorex Transplantation publ AB is a Sweden-based medical device company engaged in the research, development, production and sales of medical devices within the field of organ transplantation. The Company's main product, Glycosorb-ABO, facilitates organ transplantation between different blood types. Additionally, the Company has developed complementary product variants, such as Glycosorb-ABO A/B-kolonn, designed for different patient categories, and Glycosorb-Xeno, which can facilitate transplants between animals and humans. As of December 31, 2011, Glycosorb-ABO was used in 103 transplantation centers in 22 countries. As of December 31, 2011, the Company had four wholly owned subsidiaries, namely Glycoprobe AB, Glycorex Transplantation, Glycorex UMC AB and Glycorex UBP AB.

Company Coordinates

Company Details

Scheelevagen 27 , LUND None : 223 63

Tel: 46 46 2865780

http://www.glycorex.se

Registrar Details